AstraZeneca’s ZS-9 Delay In US Gives Veltassa An Edge
FDA issued a second complete response letter to AstraZeneca’s NDA for ZS-9 for hyperkalaemia, a potential blockbuster that would compete against Vifor Pharma’s Veltassa.
You may also be interested in...
US President Ruud Dobber talked to Scrip about expanding in renal disease, balancing the fast-growing oncology portfolio against other priority disease areas, and the company's anticipated return to growth. The big challenge going into 2019, he said, is external factors. "I'm not able to change the view of the President," he said.
After delays caused by two complete response letters, AstraZeneca’s Lokelma has been approved in the US with label benefits over its major competitor, Vifor Pharma’s Veltassa.
With a new hyperkalemia therapy nearing EU markets and its injectable iron product showing strong sales growth, Switzerland’s global specialty pharma company Vifor Pharma has been able to upgrade its financial guidance for 2017.